Overview
Schilder's disease, also known as alpha-N-acetylgalactosaminidase (alpha-NAGA) deficiency, encompasses a spectrum of clinical presentations including early-onset neuroaxonal dystrophy (Schindler disease) and late-onset angiokeratoma corporis diffusum (Kanzaki disease). The condition exhibits significant variability in genotype-phenotype correlation and the relationship between biochemical markers and clinical manifestations remains unclear 1.Diagnosis
Genetic Testing: Identification of mutations in the NAGPA gene, such as E325K mutation 1.
Biochemical Assays: Measurement of urinary sialyl glycoconjugates to assess enzyme activity 1.
Immunocytochemical Studies: Examination of structural and immunocytochemical features to understand disease pathogenesis 1.
Clinical Features: Presence of characteristic neurological symptoms in early onset and angiokeratomas in late onset 1.Management
Supportive Care: Focus on managing symptoms and complications, including neurological deficits and dermatological manifestations 1.
Multidisciplinary Approach: Collaboration with neurologists, dermatologists, and genetic counselors for comprehensive care 1.
No Specific Pharmacological Treatment: Currently, no specific enzyme replacement or pharmacological therapy is established for alpha-NAGA deficiency 1.Special Populations
Pediatrics: Early onset forms require close monitoring and supportive interventions to manage neurological deterioration 1.
Comorbidities: Management should consider potential comorbidities arising from neurological and dermatological symptoms 1.Key Recommendations
Genetic Testing for Diagnosis: Confirm diagnosis through genetic testing for NAGPA gene mutations (Evidence: Moderate 1).
Comprehensive Clinical Assessment: Include biochemical assays and clinical feature evaluation for accurate diagnosis (Evidence: Moderate 1).
Multidisciplinary Support Essential: Implement a multidisciplinary approach for optimal management of patients (Evidence: Expert opinion 1).References
1 Sakuraba H, Matsuzawa F, Aikawa SI, Doi H, Kotani M, Nakada H et al.. Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler/Kanzaki disease). Journal of human genetics 2004. link